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SHORT COMMUNICATION
The expression of mouse CLEC-2 on leucocyte subsets
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and inflammatory state
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Steve P. Watson1, Christopher D. Buckley3 and Guillaume E. Desanti3
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3 Centre for Translational Inflammation Research, Rheumatology Research Group, University
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Expression of mouse C-type lectin-like receptor 2 (CLEC-2) has been reported on circu-
lating CD11bhigh Gr-1high myeloid cells and dendritic cells (DCs) under basal conditions,
as well as on a variety of leucocyte subsets following inflammatory stimuli or in vitro
cell culture. However, previous studies assessing CLEC-2 expression failed to use CLEC-
2-deficient mice as negative controls and instead relied heavily on single antibody clones.
Here, we generated CLEC-2-deficient adult mice using two independent approaches and
employed two anti-mouse CLEC-2 antibody clones to investigate surface expression on
hematopoietic cells from peripheral blood and secondary lymphoid organs. We rule out
constitutive CLEC-2 expression on resting DCs and show that CLEC-2 is upregulated in
response to LPS-induced systemic inflammation in a small subset of activated DCs iso-
lated from the mesenteric lymph nodes but not the spleen. Moreover, we demonstrate for
the first time that peripheral blood B lymphocytes present exogenously derived CLEC-2
and suggest that both circulating B lymphocytes and CD11bhigh Gr-1high myeloid cells lose
CLEC-2 following entry into secondary lymphoid organs. These results have significant
implications for our understanding of CLEC-2 physiological functions
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Introduction
Many physiological functions are critically regulated by fine-
tuned interactions between diverse subsets of hematopoietic and
Correspondence: Dr. Guillaume E. Desanti
e-mail: g.desanti@bham.ac.uk
nonhematopoietic cells within primary and secondary lymphoid
organs (SLOs) as well as in the circulation. These interactions
are mediated by surface receptors or secreted molecules that dis-
play complex cellular, spatial, and temporal expression patterns. A
deep understanding of these patterns is required for a full knowl-
edge of their physiological significance and for effective therapeu-
tic intervention. For example, expression of receptor activator of
NFκB ligand by bone osteoblasts regulates bone density while its
C© 2015 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
www.eji-journal.eu
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expression by developing thymocytes regulates medullary thymic
epithelial cell maturation (for review; [1]).
A similar scenario can be considered for the C-type lectin-like
receptor 2 (CLEC-2) and its ligand podoplanin (PDPN), which are
involved in a variety of physiological and pathophysiological pro-
cesses (for review: [2]). While CLEC-2 expression is restricted to
hematopoietic cells, PDPN is more ubiquitously expressed, with
constitutive expression in the lungs [3], kidneys [4], brain [3],
thymus [5], SLOs [6, 7], lymphatic vessels, and bones [8]. PDPN
expression is also upregulated at the leading edge of tumors and in
additional hematopoietic and nonhematopoietic cell types during
inflammation (for review: [2]). CLEC-2/PDPN interactions play
essential roles in the immune system, as they prevent blood–lymph
mixing [9–11], are required for lymph node (LN) development
[12] and maintenance of LN vascular integrity [12, 13] and con-
tribute to the generation of optimal adaptive immune responses
[12, 14, 15].
CLEC-2 surface expression on platelets was first demonstrated
in humans [16] and soon after in mouse [17] and chicken [18].
The expression of CLEC-2 and its RNA transcript – encoded by
the C-type lectin domain family 1, member B (Clec1b) gene –
has also been studied in leucocytes isolated from different species
leading to a rather confusing mosaic of results. While CLEC-2
is absent from chicken leucocytes [18] and restricted to liver-
resident Ku¨ppfer cells in human [19–22], a much broader expres-
sion profile of CLEC-2/Clec1b has been reported in rodent leuco-
cytes, particularly in mice.
While one report claims that mouse CLEC-2 surface expression
by leucocytes is restricted to monocytes and liver-resident Ku¨ppfer
cells [20], other studies using a different antibody clone (17D9), or
the fusion protein PDPN-Fc, reported that CLEC-2 is constitutively
expressed by CD11bhigh Gr-1high cells isolated from bone marrow
(BM) and whole blood, splenic B lymphocytes, a small subset
of splenic natural killer (NK) cells, splenic plasmacytoid dendritic
cells (pDCs), splenic conventional DCs (cDCs), GM-CSF stimulated
BM-derived DCs (BMDCs), Flt3L BMDCs, as well as peripheral LN
DCs [19, 23, 24]. With the exception of NKT cells and T lym-
phocytes, in vivo LPS challenge has been reported to upregulate
CLEC-2 expression in almost all splenic leucocyte subsets as well
as peripheral LN DCs [23, 24]. In a thioglycolate-induced peri-
toneal inflammation model, CLEC-2 expression was observed in
F4/80+ macrophages but not in CD11bhigh Gr-1high cells [19, 23].
Notably, CLEC-2-deficient negative control cells were not included
in most of these studies [19, 23]. Our study aimed to clarify these
contradictory findings and improve our understanding of CLEC-
2 expression on mouse leucocytes. These results have important
physiological consequences that will be discussed below.
Results and discussion
Peripheral blood B lymphocytes and CD11bhigh Gr-1high
cells present CLEC-2 on their surface
Previous studies that investigated the temporal, spatial, and
proinflammatory expression of CLEC-2 in the murine adult
hematopoietic system have been hampered by the high neona-
tal mortality rate (>95%) of Clec1b−/− mice [10, 20], impeding
the inclusion of appropriate Clec1b−/− negative control cells in
previous studies aiming to define the temporal, spatial, and postin-
flammatory expression of CLEC-2 in vivo [19, 23, 24].
To circumvent the neonatal mortality rate of Clec1b−/−
mice, we developed a tamoxifen-inducible Clec1b deleting
mouse line (Clec1bfl/flxRosa26+/creERT2). After 6 months on
tamoxifen diet, peripheral blood leucocytes isolated from
Clec1bfl/flxRosa26+/creERT2 mice but not Clec1bfl/fl littermate con-
trols show genomic deletion of the Clec1b locus (Supporting Infor-
mation Fig. 1).
In parallel, we investigated CLEC-2 expression on hematopoi-
etic cells isolated from lethally irradiated wild-type (WT) adult
mice reconstitutedwith foetal liver (FL) cells from E14.5 Clec1b+/+
or Clec1b−/− embryos [25]. This second experimental strategy was
used to rule out potential side effects of tamoxifen on CLEC-2
expression. It is known that sex steroid hormones and their syn-
thetic derivatives (such as tamoxifen) affect hematopoiesis due to
the presence of estrogen receptors on most immune cells [26, 27].
Moreover, tamoxifen has anti-inflammatory effects that could
counteract LPS-mediated proinflammatory challenges [28–30]. In
addition, we used two different antibody clones, 17D9 [19, 23]
and INU1 [31], reported to bind to mouse CLEC-2.
Initially, CLEC-2 expression was measured on circulating
platelets, T lymphocytes, B lymphocytes, and CD11bhigh Gr-1high
cells from Clec1bfl/flxRosa26+/creERT2 mice and Clec1bfl/fl littermates
by flow cytometry using the two antibody clones 17D9 and INU1
(Fig. 1A and Supporting Information Fig. 2). Following tamoxifen
treatment, Clec1bfl/flxRosa26+/creERT2 platelets showed full abroga-
tion of CLEC-2 expression compared to Clec1bfl/fl littermates using
both 17D9 and INU1 (Fig. 1A), confirming the efficiency of our
inducible genetic mouse model.
On platelets, INU1 staining was found to be weaker than
17D9 staining in both control animals (Clec1bfl/fl mice treated
with tamoxifen and Clec1bfl/flxRosa26+/creERT2 mice fed with nor-
mal diet). Furthermore, the geometric mean fluorescence intensity
associated with 17D9 binding to leucocytes was on average three-
fold lower than that observed on platelets (Fig. 1A), while INU1
discrimination power was too weak for detecting CLEC-2 on leu-
cocytes (Fig. 1A). As a result, we solely used the 17D9 clone to
further investigate CLEC-2 expression on leucocytes.
In both the tamoxifen-inducible and radiation chimeric CLEC-
2-deficient mousemodels, the levels of 17D9 binding to circulating
B lymphocytes were significantly reduced compared to controls
(Fig. 1A and B), suggesting that peripheral blood B lymphocytes
constitutively express CLEC-2. Although CLEC-2 appeared to be
downregulated on circulating B lymphocytes following LPS treat-
ment in chimeric mice, this was not statistically significant (Fig.
1B), indicating that activated Clec1b+/+ B lymphocytes remain
positive for CLEC-2 when compared to their activated Clec1b−/−
B lymphocyte counterparts.
In the absence of LPS-induced inflammation, CD11bhigh
Gr-1high cells (which includes a mix of monocytes, granulo-
cytes/neutrophils, and a small subset of NK cells [32, 33])
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
www.eji-journal.eu
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Figure 1. CLEC-2 is present at the surfaces of peripheral blood platelets, B cells, and CD11bhigh Gr-1high cells at steady state.
(A) Clec1bfl/flxRosa26+/creERT2 (CRE TAM) and Clec1bfl/fl littermate controls (LOX TAM) were fed tamoxifen-supplemented diet from 6–8 weeks old
for 6 months. Clec1bfl/flxRosa26+/creERT2 mice (11–14 weeks old) fed conventional diet only were used as controls (CRE Control). Blood was drawn
from the tail vein, the erythrocytes were lysed and the remaining leucocytes stained with fluorochrome-conjugated antibodies. CLEC-2 expression
on platelets, B lymphocytes, and myeloid cells was assessed using the 17D9 (white symbols) or INU1 (black symbols) antibody clones compared
to their respective isotype controls by flow cytometry. The staining intensities are expressed by the geometric mean of fluorescence intensity
(Geo. M.F.I). (B) Wild-type (WT) animals were lethally irradiated (2 × 450 rad) and injected i.v. with FL cells from Clec1b+/+ (WT FL) or Clec1b−/−
(KO FL) E14.5 embryos. Six to eight weeks postinjection animals were challenged with 25 μg LPS by i.p. injection (WT FL LPS or KO FL LPS, black
symbols) and compared to nonchallenged animals (WT FL Control or KO FL Control, white symbols). Sixteen to eighteen hours post LPS injection,
blood was harvested by full exsanguination and processed as described above. Each symbol represents a sample from an individual mouse. Bars
represent the means. The graphs summarize one to three independent experiments pooled together. Statistical significance was measured by a
Mann–Whitney test with a 95% confidence interval, where: *p < 0.05; **p < 0.005; ***p < 0.0005; N.S., not significant.
isolated from Clec1b−/− reconstituted animals were negative
for CLEC-2 compared to Clec1b+/+ littermates (Fig. 1B). This
demonstrates that circulating CD11bhigh Gr-1high cells constitu-
tively express CLEC-2 in line with previous reports [19, 23].
However, treatment with tamoxifen led to the loss of specific
CLEC-2 staining, since no significant difference was observed
between Clec1bfl/flxRosa26+/creERT2 mice and their controls (Fig.
1A). Tamoxifen is known to inhibit B lymphocyte and DC matura-
tion by altering the surface membrane expression of molecules
such as CD22 on B lymphocytes or MHC-II and CD86 on
BMDCs [34, 35]. Additional uncharacterized phenotypic changes
leading to the appearance of new CLEC-2-independent bind-
ing sites might explain the nonspecific binding of 17D9 to
Clec1bfl/flxRosa26+/creERT2 B lymphocytes and CD11bhigh Gr-1high
cells as the WT Clec1b DNA was undetectable in these cells (Fig.
1A, Supporting Information Fig. 1).
Similarly, after LPS challenge, 17D9 acquired the ability to
bind to Clec1b−/− CD11bhigh Gr-1high cells leading to a 3.7-fold
higher geometric mean fluorescence intensity than in equivalent
unstimulated cells (Fig. 1B). This suggests that 17D9 binds to
CD11bhigh Gr-1high cells in a CLEC-2-independent manner follow-
ing LPS activation. In T lymphocytes, there was no evidence for
17D9 binding in any of our experimental conditions (Supporting
Information Fig. 3).
From these findings, we suggest that mouse peripheral blood B
lymphocytes and CD11bhigh Gr-1high cells present CLEC-2 on their
surface at a much lower level than platelets. These data contrast
with the lack of evidence for CLEC-2 expression in peripheral blood
leucocytes in chickens or humans [18, 21] and with the absence of
significant Clec1b transcripts in human leucocyte subsets according
to microarray analyses on the BioGPS database [21, 36]. This
indicates that, while CLEC-2 expression by platelets is conserved
through species, the presence of CLEC-2 on B lymphocytes and
CD11bhigh Gr-1high cells is specific to mice. Whether the presence
of CLEC-2 on these cells provides any particular features to the
mouse immunological system remains unknown. Our data add to
previous reports establishing important differences between the
mouse and human immune systems [37].
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. In SLOs, CLEC-2 expression by leuco-
cytes is restricted to a subpopulation of acti-
vated DCs. At 6–8 weeks old, Clec1b+/+ (WT
FL) or Clec1b−/− (KO FL) FL chimeras were
challenged with 25 μg LPS by i.p. injection
(WT FL LPS or KO FL LPS, black symbols) and
compared to nonchallenged animals (WT FL
Control or KO FL Control, white symbols). Six-
teen to eighteen hours after LPS injections,
the spleen and MLN were harvested, the ery-
throcytes were lysed and the remaining leu-
cocytes stained with fluorochrome-conjugated
antibodies. CLEC-2 expression on (A) B cells,
(B) CD11bhigh Gr-1high cells, (C) CD11bneg/int DCs,
and (D) CD11bhigh DCs was assessed using the
17D9 antibody compared to its respective iso-
type control by flow cytometry. The stain-
ing intensities are expressed as the geomet-
ric mean of fluorescence intensity (Geo. M.F.I).
Each symbol represents a sample from an indi-
vidual mouse and bars represent means. The
graphs summarize three independent experi-
ments pooled together. (E) Relative expression
of Clec1b transcript in leucocytes isolated from
the spleen and the MLN. C57BL/6 mice were
injected i.p. with PBS (white bars) or 25 μg LPS
(black bars). Sixteen and eighteen hours later
the spleen and MLN were harvested, the ery-
throcytes were lysed and the remaining leu-
cocytes stained. Leucocyte populations were
isolated by FACS based on the following phe-
notypes: T cells (T): DAPIneg CD41neg F4/80neg
CD11cneg CD19neg B220neg CD3εpos CD8α/CD4pos;
B cells (B): DAPIneg CD41neg F4/80neg CD11cneg
CD8αneg CD3εneg B220pos CD19pos; NK cells
(NK): DAPIneg CD41neg CD19neg CD8αneg CD4neg
CD3εneg NK1.1/NKp46pos; CD11bpos F4/80neg
cells: DAPIneg CD41neg CD19neg CD3εneg F4/80neg
CD11bpos; F4/80pos CD11bint cells: DAPIneg
CD41neg CD19neg CD3εneg CD11bint F4/80pos;
cDC CD11bneg/int cells: DAPIneg CD41neg CD19neg
CD3εneg B220neg CD11cpos CD11bneg/int; cDC
CD11bhigh cells: DAPIneg CD41neg CD19neg
CD3εneg B220neg CD11cpos CD11bhigh. After
mRNA isolation and cDNA preamplification for
the genes of interest, the samples were ana-
lyzed by quantitative PCR. The signal for Clec1b
was normalized against the house-keeping
gene Actnb (β-actin). Total BM isolated from
PBS-injected mice was used as positive control
while the T cells coming from these animals
were used as reference to set the arbitrary unit.
Each population was isolated from three to five
independent cell sorting experiments including
one LPS-injected and one PBS-injected mouse
for each cell sorting, with the exception of the
F4/80pos CD11bint control and LPS-stimulated
cells for which n = 2 experiments. Data are
shown as mean + SEM. Statistical significance
was measured by a Mann–Whitney test with a
95% confidence interval where: *p < 0.05; **p <
0.005; ***p < 0.0005; N.S., not significant.
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Most SLO-resident leucocytes do not express
CLEC-2/Clec1b at steady state
At steady state, we observed comparable 17D9 binding to spleen
and mesenteric LN (MLN) B lymphocytes, CD11bhigh Gr-1high
cells, pDCs, CD11bneg/int cDCs, and CD11bhigh cDCs isolated from
Clec1b−/− radiation chimeras or their WT counterparts (Fig. 2,
Supporting Information Figs. 4 and 5). These results, that demon-
strate a lack of CLEC-2 expression on these leucocytes, contradict
previous observations made using the 17D9 antibody clone and
PDPN-Fc recombinant protein that suggested that mouse CLEC-2
was constitutively expressed on all these cell types in spleen and
on peripheral LNs’ cDCs [23, 24]. Moreover, we could not detect
significant Clec1b transcript levels in most of the leucocyte popula-
tions isolated from the spleen and the MLN (Fig. 2E). The absence
of Clec1b transcripts in most resting leucocytes is supported by two
independent microarray analyses performed by the ImmGen [38]
and BioGPS [36] consortia (Supporting Information Fig. 6).
Interestingly, in agreement with the ImmGen database, we
did observe that CD11bint F4/80pos red pulp splenic macrophages
express high levels of Clec1b transcripts (Fig. 2E). However, we
were unable to detect surface CLEC-2 on the surface of these cells
when comparing our FL-reconstituted animals (data not shown).
Given that F4/80pos red pulp splenic macrophages, which express
PDPN, play a key physiological role in the clearance of senescent
blood erythrocytes and platelets by phagocytosis [6, 39, 40], the
Clec1b transcripts detected in these cells are likely to derive from
engulfed platelets.
These results suggest that CLEC-2 surface expression by periph-
eral blood B lymphocytes and CD11bhigh Gr-1high cells (Fig. 1) is
lost upon entry into SLOs (Fig. 2). The majority of mouse B lym-
phocytes and pre-cDC monocytes migrating from peripheral blood
toward LNs enter via high endothelial venules (HEVs), arriving in
the T-cell zone, which is rich in PDPNpos fibroblastic reticular cells
(FRCs) [41]. Downregulation or shedding of CLEC-2 by B lympho-
cytes and CD11bhigh Gr-1high cells during their entry through the
HEVs might represent a functional mechanism to prevent inappro-
priate activation of PDPNpos FRCs in the absence of infection. In
this context, recent studies demonstrated that close interactions
between antigen-activated CLEC-2pos DCs and LN PDPNpos FRCs
are required for mounting an effective immune response by favor-
ing DC recruitment, FRCs activation and LN swelling [14, 15, 24].
Most SLO-resident leucocytes remain CLEC-2-negative
following LPS stimulation
CLEC-2 was not upregulated on splenic and MLN-resident B lym-
phocytes, CD11bhigh Gr-1high cells, pDCs, or CD11bneg/int cDCs in
response to intraperitoneal (i.p.) LPS challenge of Clec1b−/− and
Clec1b+/+ reconstituted animals (Fig. 2A–C and Supporting Infor-
mation Fig. 5). It has been shown that B lymphocyte stimulation
via LPS/TLR4 favors their emigration from the blood into SLOs
[42]. Interestingly, we could not observe any CLEC-2pos B lym-
phocytes in the SLOs of LPS-stimulated mice (Fig. 2), supporting
the observation that circulating activated B lymphocytes down-
regulate CLEC-2 before entering into SLOs (Fig. 1B). Kerrigan
and collaborators have suggested the same CLEC-2 downregula-
tion process by circulating CD11bhigh Gr-1high cells upon reaching
inflammatory sites [19]. As entry to both SLOs and inflamma-
tory sites requires leucocyte rolling, arrest, and transendothelial
migration [41], it is tempting to suggest that CLEC-2 downregu-
lation or shedding by these leucocytes facilitates the completion
of this three-step mechanism. Indeed, it has been shown that the
shedding of transmembrane molecules is essential for leucocyte
transendothelial migration [43–46]. We hypothesize that CLEC-2
could be lost via the same mechanisms.
CD11bhigh Gr-1high cells, pDCs, and CD11bneg/int cDCs isolated
from LPS-stimulated Clec1b−/− mice exhibited a higher level of
17D9 binding than Clec1b−/− nonchallenged counterparts. Once
again, these results indicate that the 17D9 antibody clone has
the capacity to bind LPS-stimulated leucocytes in a CLEC-2-
independent manner. The lack of Clec1b transcript upregulation in
LPS-stimulated leucocytes (Fig. 2E) provides further evidence to
support this conclusion and challenges previously described LPS-
induced CLEC-2 upregulation by most splenic resident leucocytes
and peripheral LN cDCs [23, 24].
MLN but not splenic CD11bhigh cDCs acquire CLEC-2
following LPS stimulation
In agreement with the results detailed above, CLEC-2 expression
was not detected on splenic CD11bhigh cDCs. However, a mod-
est but significant increase in staining of MLN-derived Clec1b+/+
CD11bhigh cDCs compared to Clec1b−/− controls was observed
after LPS injection (Fig. 2D), indicating that LPS-stimulated MLN
CD11bhigh cDCs have the capacity to upregulate CLEC-2 (Fig. 2D).
However, we could not correlate the appearance of CLEC-2 on
the membrane with a higher relative amount of Clec1b transcripts
in the stimulated CD11bhigh cDCs (Fig. 2E), suggesting that LPS
stimulation regulates CLEC-2 expression in MLN CD11bhigh cDCs
via posttranscriptional mechanisms.
Taken together, our results confirmed high levels of CLEC-2
expression on splenic platelets (data not shown), while no sig-
nificant expression of CLEC-2 was observed on most leucocyte
populations investigated, both at steady state and after LPS injec-
tion. However, we did observe an increase in CLEC-2 expression
on activated CD11bhigh cDCs isolated from the MLN. This increase
was absent on splenic-activated cDCs.
The existence of cell-specific and tissue-specific regulation of
CLEC-2 expression has previously been observed in the context
of human rheumatoid arthritis, a chronic inflammatory disease
where CLEC-2 expression was found to be restricted to tissue infil-
trating platelets, while absent from activated DCs [22]. In contrast,
FITC skin painting, FITC footpad immunization, or OVA/CFA sub-
cutaneous injections in mice were found to contribute to the gen-
eration of an immune response that relies on CLEC-2 expression
by activated DCs and their interaction with PDPNpos lymphatic
endothelial cells and PDPNpos FRCs [14, 15, 24]. These studies
C© 2015 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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demonstrate that CLEC-2 upregulation is a characteristic of locally
activated DCs migrating toward the draining LN [14, 15, 24] and
not the systemic feature of an activated immune system [23]. In
accordance with this, we only observed CLEC-2 upregulation by
activated DCs in the MLN, a SLO close to the LPS site of adminis-
tration (i.e. the peritoneal cavity), but not in a remote SLO such as
the spleen. This suggests that the MLN CLEC-2pos CD11bhigh cDCs
we observed may have recently migrated from the surrounding
mesenteric tissue following LPS administration.
Normal lymphocyte homeostasis in B cell Clec1b−/−
mice as B cells do not produce CLEC-2
To gain insight into the potential physiological roles of CLEC-2
in B lymphocytes, we first visualized the LNs from B lymphocyte-
deficient Jh−/− κ−/− mice and saw no evidence of erythrocyte
infiltration in the LNs, similar to WT animals (Fig. 3A), indicating
that CLEC-2 on B lymphocytes does not play an important role in
blood–lymph separation or the maintenance of HEVs.
In order to investigate if CLEC-2 on peripheral blood B lympho-
cytes contributes to lymphocyte homeostasis, we generated mice
with a Clec1b−/− deficiency restricted to the B-cell lineage by mix-
ing Clec1b−/− FL and Jh−/− κ−/− BM cell suspensions (at a 1:9
ratio) that we injected into lethally irradiated C57BL/6 recipients
(Supporting Information Fig. 7A) [47]. The absolute numbers of
lymphocytes in the blood, spleen, and MLNs were monitored (Fig.
3B and C, Supporting Information Fig. 7B and C). Both in the
blood and the SLOs, the absolute numbers of B and T lymphocytes
were normal. In the spleen, the numbers of follicular, nonfollicu-
lar, and marginal zone Clec1b−/− B lymphocytes were comparable
to the controls. Contrary to the MLNs, a small increase in CD4+
T lymphocytes was observed in the spleen of Clec1b−/− animals.
However, no-significant increase in na¨ıve (CD62Lhi CD44int) or
activated (CD44hi CD62L−) CD4+ T lymphocytes was noted in
these animals. Similarly, the CD4− T lymphocytes showed the
same level of activation between Clec1b−/− and control animals.
These results indicate that deletion of the Clec1b gene in the B-cell
lineage has no effect on lymphocyte homeostasis.
Despite the absence of a functional Clec1b gene, peripheral
blood Clec1b−/− B lymphocytes were stained by 17D9 at the
same level as Clec1b+/+ B lymphocytes (Fig. 3D). In B lympho-
cyte Clec1b-deficient mice, 71% of the platelets were CLEC-2pos
on average (Fig. 3D), while the level of CLEC-2 expression by
CD11bhigh Gr-1high cells was comparable to that found in controls
(Supporting Information Fig. 7D). We compared the amount of
Clec1b transcripts by quantitative PCR in B lymphocytes isolated
from the peripheral blood, MLNs, and spleen. In all three popula-
tions, the amount of Clec1b was extremely low and at a compara-
ble level (Fig. 3E). This last result corroborates a study on rat B
lymphocytes showing that Clec1b transcripts are hardly detectable
in these cells [48]. From these observations, we conclude that
peripheral blood B lymphocytes do not intrinsically express
CLEC-2. Instead we propose that the CLEC-2 molecules detected
on the surface of circulating B lymphocytes are derived fromMHC-
II antigen presentation, trogocytosis, or exosomes/microparticles
attached to the B-cell membrane [49].
Concluding remarks
Our study confirms that CLEC-2 is constitutively expressed by
mouse platelets and circulating CD11bhigh Gr-1high myeloid cells
and shows for the first time that CLEC-2 is present on the sur-
face of peripheral blood B lymphocytes. These B cells do not pro-
duce CLEC-2 but likely acquire CLEC-2 molecules from other yet
uncharacterized cell types. Our data suggest that both circulating
B lymphocytes and CD11bhigh Gr-1high myeloid cells lose CLEC-2
when entering SLOs. This loss of CLEC-2 might depend on the
same mechanisms that are selectively shedding CD23 and CD62L
from leucocytes during transendothelial migration [43, 45, 46].
As CLEC-2 stimulates PDPNpos FRCs in SLOs in order to mount
a proper immune response [14, 15, 24], we propose that the
loss of CLEC-2 by na¨ıve B lymphocytes and CD11bhigh Gr1high
myeloid cells entering in the SLOs might be a prerequisite to pre-
vent untimely FRCs activation in absence of antigenic challenge.
The use of animals reconstituted with Clec1b−/− FL and the
measurements of Clec1b transcripts allowed us to rule out any
constitutive CLEC-2 expression by most of the leucocyte subpop-
ulations isolated from SLOs. We also demonstrated that isotype
controls are not adequate when working with the 17D9 anti-
body clone. Finally, we showed that LPS peritoneal injection
induces CLEC-2 acquisition to the unique MLN-activated DCs leu-
cocyte population. Taken together with other studies, our findings
emphasize the notion that the expression of CLEC-2 is not only
restricted to specific subsets of resting leucocytes and platelets
but is determined both by the activation state and anatomical site
where immune responses take place.
Materials and methods
Mice and diets
Clec1b+/− [25], Clec1bfl/fl [25], Rosa26+/ERT2cre (Jackson Labora-
tory, ME) [50], Clec1bfl/fl x Rosa26+/ERT2cre, Jh−/− κ−/− [51, 52],
and BoyJ mice were maintained in the Biomedical Services Unit,
University of Birmingham. C57BL/6 mice were purchased from
Harlan, UK. Animals were fed with FormulaLab Diet 5008 (Lab-
Diet, St-Louis, MO). When required, 6- to 8-week-old Clec1bfl/fl
× Rosa26+/ERT2cre and their Clec1bfl/fl x Rosa26+/+ control litter-
mates were continuously fed with tamoxifen-supplemented diet
TAM 400 (Harlan, UK). For isolation of embryonic FL, the morn-
ing of vaginal plug detection was designated day 0.5 of gestation.
Animal experiments were performed in accordance with UK Home
Office legislation.
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Figure 3. B lymphocyte-specific Clec1b deficiency does not affect lymphocyte homeostasis as CLEC-2 molecules on circulating B cells are exoge-
nously derived. (A) Cervical lymph nodes (CLNs), inguinal lymph nodes (ILNs), and MLN were isolated from WT and B-cell deficient Jh−/− κ−/−
mice and imaged. The picture is representative of five WT and six B-cell deficient mice. Red bars represent 5 mm. (B–D) Irradiated recipient mice
were reconstituted with a mix of 2 × 105 Clec1b+/+ or Clec1b−/− E14.5 FL cells and 18 × 105 Jh−/− κ−/− BM cells. Seven to nine weeks later, the
blood, spleen, and MLNs were isolated and analyzed by flow cytometry to determine (B and C) leucocyte numbers and (D) CLEC-2 expression was
assessed using the 17D9 antibody compared to its respective isotype control. Each symbol represents an individual mouse and bars represent
means. The graphs summarize two independent experiments pooled together. (E) Platelets and B lymphocytes were isolated from the blood, MLN,
and the spleen of C57BL/6 mice by FACS, based on the following phenotypes: platelets: FSClow CD41pos; B cells: FSChi CD41neg DAPIneg CD3εneg
CD19pos. After mRNA isolation and cDNA synthesis, the relative expression of Clec1b transcripts was analyzed by quantitative PCR. The signals
for Clec1b was normalized against the house-keeping gene Actnb (β-actin). Total BM was used as positive control and reference to set the arbitrary
unit. Each population was isolated from three independent cell sorting experiments, including one to two mice for each cell sorting, and one
quantitative PCR was ran from each cell sorting. The graphs summarize these three independent quantitative PCRs pooled together and data are
shown as mean + SEM. Statistical significance was measured by a Mann–Whitney test with a 95% confidence interval where: *p < 0.05; **p < 0.005;
***p < 0.0005; N.S, not significant.
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Mouse hematopoietic system reconstitution
C57BL/6 or BoyJ mice (8–10 weeks old) were given Baytril in the
drinking water for 7 days prior to irradiations with two doses of
450rad, 3 h apart. One hour after the last irradiation Clec1b+/+ or
Clec1b−/− E14.5 FL cells were injected intravenously (i.v.). For the
generation of B-cell Clec1b-deficient recipients, 2 × 105 Clec1b+/+
or Clec1b−/− E14.5 FL cells were mixed with 18 × 105 Jh−/− κ−/−
BM cells. Mice were left for 6- to 8-weeks postinjection before
analysis or further challenged by i.p. injection of 25 μg of LPS
(Chondrex) diluted in PBS or PBS only. Mice were analyzed 16–
18 h post LPS or PBS injection. Successful LPS injections were
confirmed by 5% weight loss over this period.
Tissue sampling and preparation
In all cases, cell centrifugation was performed at the average force
of 275 g for 4 min. Blood was sampled from the tail vein of
Clec1bfl/fl; Rosa26+/ERT2cre; or Clec1bfl/fl × Rosa26+/ERT2cre mice into
20 mM EDTA/PBS 1× solution. After centrifugation, the super-
natant was removed and the pellet resuspended in red blood cell
lysis buffer (Sigma-Aldrich) at room temperature for 5 min. Sam-
ples were centrifuged and resuspended in cold PBS 1×, 2% foetal
calf serum (FCS), 2 mM EDTA solution and stained for flow cytom-
etry analysis or processed for genomic DNA extraction.
Whole blood from FL reconstituted animals was drawn into
acid citrate dextrose solution (9:1 v/v) from the inferior vena cava
under isofluorane anesthesia and mixed to 20 mM EDTA/PBS 1×
solution. An aliquot of blood was centrifuged and processed as
described above.
The spleen and the MLN were harvested into cold 2% FCS
RPMI solution (Sigma-Aldrich). For cell sorting of T cells, B cells,
and NK cells, part of the spleen was mechanically dissociated on a
100 mm mesh (Greiner Bio-one). In all the other cases, spleen or
MLN were teased apart with dissection forceps in a 2% FCS RPMI
solution containing 2.5 mg/mL of Collagenase D (Roche) and
2 mg/mL of DnaseI (Sigma-Aldrich). Cell suspensions were kept
under magnetic stirring at 37°C for 45 min before centrifugation.
Pellets were resuspended in a 2% FCS RPMI solution containing
2.5 mg/mL of Collagenase/Dispase (Roche) and 2 mg/mL of Dna-
seI (Sigma-Aldrich) and kept under magnetic stirring at 37°C for
30 min. Cell suspensions were adjusted to a final EDTA concen-
tration of 5 mM by the addition of a 0.5 M EDTA solution and
kept under magnetic stirring at 37°C for 5 min. Cell suspensions
were centrifuged and the pellets resuspended in red blood cell
lysis buffer (Sigma-Aldrich) as described above before processing
for FACS staining.
Antibodies, FACS analysis, and cell sorting
The full list of antibodies used is provided in Supporting Infor-
mation Table 1. Anti-mouse CLEC-2-FITC 17D9 clone was mainly
obtained from a commercial provider (AbD Serotec, 17D9) and
compared to rat IgG2b-FITC (AbD Serotec, MCA1125FT). For
some experiments, purified 17D9 (a kind gift from Caetano
Reis e Sousa, Cancer Research UK, London) and purified rat
IgG2b (R&D Systems) were used. Purified anti-mouse CLEC-2
INU1 clone (a kind gift from Bernhard Nieswandt, University of
Wu¨rzburg, Germany) was used in conjunction with purified rat
IgG1k (Biolegend, 400402). All purified antibodies were conju-
gated to AlexaFluor R©488 using a monoclonal antibody labeling
kit (Invitrogen).
Cells were stained with antibodies at 4°C in the dark in PBS
1×, 2% FCS, 2 mM EDTA solution. Cells were washed and cen-
trifuged twice before being resuspended in a cold a PBS 1×, 2%
FCS, 2 mM EDTA, 1 mg/mL DAPI solution. Flow cytometry acqui-
sitions were performed on a three laser (405, 488, 633 nm) Cyan
(Beckman Coulter) using Summit v4.3 software (Beckman Coul-
ter). Flow cytometry cell sorting was performed on a MoFlo high-
speed cell sorter and Astrios cell sorter (Beckman Coulter) using
Summit software (Beckman Coulter). FACS data were analyzed
with FlowJo software 8.7 (Tristar).
Quantitative PCR
Total BM was flushed with 2% FCS RPMI from the tibia and femur
of both hind legs. A tenth of the cell suspension was centrifuged,
the supernatant was removed and pellets were snap frozen on dry
ice. Flow cytometry cell sorted cells were collected in PBS 1×,
2% FCS, 2 mM EDTA solution, centrifuged, pelleted, snap frozen
on dry ice and stored at −80°C. mRNA was extracted using a
“RNeasy Microkit” (Qiagen) following the manufacturer’s instruc-
tions. cDNA was generated using the “High Capacity Reverse
Transcription” kit and random primers mix (Applied Biosystems).
RT-PCR reaction settings were: 25°C, 10 min; 37°C, 120 min;
85°C, 10 min. The cDNA obtained was diluted 1:2 with RNase-
free/DNase-free water (Qiagen), preamplified using the “TaqMan
Pre-Amp Master Mix” kit (Applied Biosystems) and the TaqMan
probes (Applied Biosystems) specific for murine β-actin (Actnb,
probe number: Mm 01205647-g1), β-2microglobulin (B2m, probe
number: Mm 00437762-m1) and CLEC-2 (Clec1b, probe num-
ber: Mm 0183353-m1). The preamplification PCR reaction set-
tings were 95°C, 10 min followed by ten cycles: (95°C, 15 s;
65°C, 4 min). These preamplified cDNA were diluted 1:5 with
RNase-free/DNase-free water (Qiagen). The TaqMan probe-based
quantitative PCR was set up on a 384 well/plate using “TaqMan
Gene Expression Master Mix”(Applied Biosystems) and the Taq-
Man probes for the murin Actnb, B2m, and Clec1b mentioned
above. The quantitative PCR reactions were run on a 7900HT
quantitative PCR machine (Applied Biosystems) at 50°C, 2 min;
95°C, 10 min; 40 cycles: (95°C, 15 s; 60°C, 1 min).
Statistical analysis
All statistical analyses were performed on Prism v4.0 (GraphPad
Software, CA) using two-tailed Mann–Whitney tests with 95%
confidence interval.
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